Improvement of cardiac function in thalassemia major treated with L-carnitine

Acta Haematologica

Volumn 111, Issue 3, 2004, Pages 143-148

  El Beshlawy, Amal ^a,d   Ragab, Lamis ^a   Fattah, Alia Abdel ^a   Ibrahim, Ilham Youssry ^a   Hamdy, Mona ^a   Makhlouf, Ali ^a   Aoun, Elie ^b   Hoffbrand, Victor ^c   Taher, Ali ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d Royal Free Hospital ^*  (Egypt)

Author keywords

Cardiac function; L Carnitine; Thalassemia major

Indexed keywords

CARNITINE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MEDICAL ASSESSMENT; MULTIGATED EQUILIBRIUM RADIONUCLIDE ANGIOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; SCINTIANGIOGRAPHY; SYSTOLIC BLOOD PRESSURE; THALASSEMIA;

ADOLESCENT; ADULT; ANGIOGRAPHY; BETA-THALASSEMIA; CARNITINE; CHILD; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HEART FUNCTION TESTS; HUMANS; MALE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 1842457048     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076522     Document Type: Article

References (31)

1. Jessup M, Manno CS: Diagnosis and management of iron induced heart disease in Cooley's anemia. Ann NY Acad Sci 1998;850/1:242-250.
2. Zurlo MG, DeStefano P, Borgna-Pignatti C: Survival and causes of death in thalassemia major. Lancet 1989;ii:27-30.
3. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
4. Lattanzi F, Bellotti P, Picano E, Chiarella F, Mazzarisi A, Melevendi C, Forni G: Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation 1993;87:748-754.
5. Olivieri NF, Nathan DG, MacMillan JH: Survival in medically treated patients with homozygous beta thalassemia. N Engl J Med 1994;331:574-578.
6. Freeman AP, Giles RW, Berdoukas AV, Talley PA, Murray IP: Sustained normalization of cardiac function by chelation therapy in thalassemia major. Clin Lab Haematol 1989;11:299-307.
7. Kucuk NO, Aras G, Sipahi T, Ibis E, Akar N, Soylu A, Erbay G: Evaluation of cardiac functions in patients with thalassemia major. Ann Nucl Med 1999;13/3:175-179.
8. Walter H: L-Carnitine. Arch Dis Child 1996;74:475-478.
9. Pepine CJ: The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 1991;13/1:2-21.
10. Colonna P, Iliceto S: Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial. Carnitine Echocardiografia Digitalizzata Infarto Miocardico. Am Heart J 2000;139/3:S124-S130.
11. Sotirakopoulos N, Athanasiou G, Tsitsios T, Mavromatidis K: The influence of L-carnitine supplementation on hematocrit and hemoglobin levels in patients with end-stage renal failure on CAPD. Ren Fail 2002;24:505-510.
12. Bahl VK, Malhotra OP, Kumar D: Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: A combined M-mode, two-dimensional, and Doppler echocardiographic study. Am Heart J 1992;124:1516-1523.
13. Levy WC, Cerqueira MD, Matsuoka DT, Harp GD, Stratton JR: Four radionuclide methods for left ventricular volume determination: Comparison of a manual and an automated technique. J Nucl Med 1992;33:763-770.
14. Iskandrian AE, Verani MS: Nuclear Cardiac Imaging: Principles and Application, ed 2. Philadelphia, Davis, 1996.
15. Armitage P, Berry G: Statistical Methods in Medical Research, ed 3. Oxford, Blackwell Scientific Publications, 1994.
16. Kothari SS, Sharma M: L-Carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998;50/1:59-61.
17. Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A: Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12/3:291-299.
18. McDonald IG: Echocardiographic assessment of left ventricular function in aortic valve disease. Circulation 1976;53:860-864.
19. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK: Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993;88:1127-1135.
20. Sau F, Lai ME, Seguro C, Onnis E, Figus A, Farci P, Balestrieri A, Cherchi A: Echocardiographic study at rest and during effort in adult asymptomatic thalassemia patients. Cardiologia 1989;34/3:221-227.
21. Kremastinos DT, Toutouzas PK, Vyssoules GP, Venetis CA, Vretou HP, Avgoustakis DG: Global and segmental left ventricular function in beta thalassemia. Cardiology 1985;72/3:129-139.
22. Spirito P, Lupi G, Melevendi C, Vecchio C: Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990;82:188-194.
23. Kono T, Sabbah HN, Rosman H, Alam M, Stein PD, Goldsein S: Left atrial contribution to ventricular filling during the course of evolving heart failure. Circulation 1992;86:1317-1322.
24. Gottsauner-Wolf M, Schedlmayer-Duit J, Porenta G, Huber K, Sochor H: Assessment of left ventricular function: Comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis. Eur J Nucl Med 1996;23:1613-1618.
25. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002;360:516-520.
26. Aldouri MA, Wonke B, Hoffbrand DM, Flynn SE: High incidence of cardiomyopathy in beta-thalassemia patients receiving regular transfusion and iron chelation. Acta Haematol 1990;84:113-117.
27. Desideri A, Scattolin G, Gabellini A, Cavuto F, Vanzelli M, Formichi M, Corbara F: Left ventricular function in thalassemia major. Protective effect of deferoxamine. Can J Cardiol 1994;10/1:93-96.
28. Corr PB, Creer MM, Yamada KA, Saffitz JE: Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989;83:927-936.
29. Yesilipek MA, Hazar V, Yegin O: L-Carnitine treatment in β-thalassemia major. Acta Hematol 1998;100/3:162-163.
30. Perrine SP, Ginder GD, Faller DV: A short-term trial of butyrate to stimulate fetal-globin gene expression in the beta globin disorder. N Engl J Med 1993;328/2:81-86.
31. Reich S, Buhrer G, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Muller C, Vetter B, Kulozik AE: Oral isobutyramide reduces transfusion requirement in some patients with homozygous beta-thalassemia. Blood 2000;96:3357-3363.